15.67  0.42 (2.75%)		06-18 16:00
Open: 15.315 High: 16.2 Volume: 1,251,955		Pre. Close: 15.25 Low: 15.315 Market Cap: 1,303(M)

Short term
Mid term
Targets	6-month :	18.92	1-year :	22.1
Resists	First :	16.2	Second :	18.92
Pivot price	14.14
Supports	First :	13.87	Second :	12.43
MAs	MA(5) :	15.14	MA(20) :	14.08
	MA(100) :	14.77	MA(250) :	12.81
MACD	MACD :	0.1	Signal :	-0.2
%K %D	K(14,3) :	77.1	D(3) :	76
RSI	RSI(14): 61.2
52-week	High :	18.6	Low :	4.8

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AMLX ] has closed below upper band by 3.9%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.22 - 16.28	16.28 - 16.33
Low:	15.16 - 15.23	15.23 - 15.29
Close:	15.56 - 15.67	15.67 - 15.77

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Thu, 18 Jun 2026
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Thu, 18 Jun 2026
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Thu, 18 Jun 2026
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey

Mon, 08 Jun 2026
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan

Mon, 08 Jun 2026
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan

Mon, 08 Jun 2026
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	111 (M)
Shares Float	84 (M)
Held by Insiders	7.9 (%)
Held by Institutions	105.3 (%)
Shares Short	14,960 (K)
Shares Short P.Month	14,800 (K)

EPS	-1.49
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.46
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-38.8 %
Return on Equity (ttm)	-63.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.87
Sales Per Share	0
EBITDA (p.s.)	-1.43
Qtrly Earnings Growth	0 %
Operating Cash Flow	-120 (M)
Levered Free Cash Flow	-72 (M)

PE Ratio	-10.59
PEG Ratio	0
Price to Book value	6.36
Price to Sales	0
Price to Cash Flow	-14.48

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.